Tag Archives: Signifor® (pasireotide)

Novartis’ Signifor® (pasireotide) intramuscular injection to treat adult patients with acromegaly approved by the European Commission

Acromegaly is a rare pituitary disorder, which requires normalization of hormonal levels to help prevent the serious consequences of the disease[1],[2],[3],[4] Approval based on two large phase III trials showing superior efficacy of new formulation of Signifor over current SSAs … Read the full press release